Survival from multiple myeloma in england and wales up to 2001

British Journal of Cancer

Volumn 99, Issue , 2008, Pages S113-S115

  Schey, S ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; STEROID;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MOLECULAR INTERACTION; MULTIPLE MYELOMA; NOTE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SOCIOECONOMICS; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ENGLAND; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; SURVIVAL ANALYSIS; WALES;

EID: 52449117622     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604608     Document Type: Article

References (34)

1. Ashcroft AJ, Davies FE, Morgan GJ (2003) Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet 4: 284–292
2. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Paven C, Bataille R (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Eng J Med 335: 91–97
3. Badros A, Barlogie B, Siegel E, Cottier-Fox M, Zangari M, Fassas A, Morris C, Anaissie E, Van Rhee F, Tricot G (2002) Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 20: 1295–1301
4. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore Jr DF, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC (2006) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24: 929–936
5. Bjorkstrand BB, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, Blade J, Carlson K, Cavo M, Ferrant A, Goldstone AH, de Laurenzi A, Majoline I, Marcus R, Prentice HG, Remes K, Samson D, Sureda A, Verdonck LF, Volin L, Gahrton G (1996) Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 88: 4711–4718
6. Blade J, Rosinol L, Sureda A, Ribera JM, Diaz-Mediavilla J, Garcia-Larana J, Mateos MV, Palomera L, Fernandez-Calvo J, Marti JM, Giraldo P, Carbonell F, Callis M, Trjillo J, Gardella S, Moro MJ, Barez A, Soler A, Font L, Fontanillas M, San Miguel J, Programa para elEstudio de la Terapeutica en Hemopatia Maligna (PETHEMA) (2005) High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106: 3755–3759
7. Blade J, San Miguel JF, Fontanillas M, Alcala A, Maldonado J, Garcia-Conde J, Conde E, Conzalez-Brito G, Moro MJ, Escudero ML, Trujillo J, Pascual A, Rozman C, Estape J, Montserrat E (1996) Survival of multiple myeloma patients who are potential candidates for early high-dose the intensification/autotransplantation and who were conventionally treated. J Clin Oncol 14: 2167–2173
8. Brenner H, Gondos A, Pulte D (2008) Recent major improvement in longterm survival of younger patients with multiple myeloma. Blood 111: 2521–2526
9. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, Glaccone L, Sorasio R, Omede P, Baldi I, Bringhen S, Massala M, Aglietta M, Levis A, Gallamini A, Fanin R, Palumbo A, Storb R, Ciccone G, Boccadoro M (2007) A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356: 1110–1120
10. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, Munshi NC, Sclossman R, Tariman J, Singhal S (2007) Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 109: 2604–2606
11. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, Anderson KC (1996) Multiple myeloma cell adhesioninduced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87: 1104–1112
12. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brwon J, Drayson MT, Selby PJ, Medical Research Council Adult Leukaemia Working Party (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348: 1875–1883
13. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163: 380–386
14. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98: 210–216
15. Dimopoulos MA, Spencer A, Attal M, Prince M, Harousseau J-L, Dmoszynska A, Yu Z, Olesnyckyj M, Zeldis J, Knight R (2005) Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010). Blood (ASH Annual Meeting Abstracts), Nov 106: 6
16. Dredge K, Marriott JB, Todryk SM, Muller GW, Chen R, Stirling DI, Dalgleish AG (2002) Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 168: 4914–4919
17. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, Macro M, Pertuiset E, Dreyfus F, Mariette X, Boccacio C, Brouet JC (1998) High-dose therapy and autologous peripheral blood stem-cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized trial. Blood 92: 3131–3136
18. Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Björkstrand B, Bladé J, Cornelissen J, de Laurenzi A, Facon T, Ljungman P, Michallet M, Niederwieser D, Powles R, Reiffers J, Russell NH, Samson D, Schaefer UW, Schattenberg A, Tura S, Verdonck LF, Vernant JP, Willemze R, Volin L, European Group for Blood and Marrow Transplantation (2001) Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centers. Br J Haematol 113: 209–216
19. Gahrton G, Tura S, Svensson H (1997) Allogeneic bone marrow transplantation in multiple myeloma: an update of the EBMT registry. Sixth International Workshop on multiple myeloma. Syllabus, Boston, MA, 1997, June 14–18. Harvard Medical School: Boston
20. Gratwohl A, Passweg J, Baldomero H, Horisberger B, Urbano-Ispizua A, Accreditation Committee of the European group for Blood and Bone Marrow Transplantation (EBMT) (2002) Economics, health care systems and utilization of haematopoietic stem cell transplants in Europe. Br J Haematol 117: 451–468
21. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI, Anderson KC (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15: 1950–1961
22. Kose KC, Cebesoy O, Akan B, Altinel L, Dincer D, Yazar T (2006) Functional results of vertebral augmentation techniques in pathological vertebral fracture of myelomatous patients. J Natl Med Assoc 98: 1654–1658
23. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M (2007) Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 25: 1993–1999
24. MacLennan ICM, Chapman C, Dunn J, Kelly K (1992) Combined chemotherapy with ABCM versus mephalan for treatment of myelomatosis. Lancet 339: 200–205
25. Mitchell JM, Meehan KR, Kong J, Schulman KA (1997) Access to bone marrow transplantation for leukemia and lymphoma: the role of sociodemographic factors. J Clin Oncol 15: 2644–2651
26. Mitsiades CS, Hayden PJ, Anderson KC, Richardson PG (2007) From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract Res Clin Haematol 20: 707–816
27. Ng AP, Wei A, Bhurani D, Chapple P, Fellepa F, Juneja S (2006) The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells. Haematologica 91: 972–975
28. Peggs KS, Mackinnon S, Yong K (2002) Reduced intensity conditioning and allogeneic stem-cell transplantation: determining its role in multiple myeloma. J Clin Oncol 20: 4268
29. Phekoo KJ, Schey SA, Richards MA, Bevan DH, Gillett D, Møller H (2004) A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in the United Kingdom. Br J Haematol 127: 299–304
30. Rajkumar SV, Lacey MO, Kyle RA (2007) Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood Rev 21: 255–265
31. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23: 630–639
32. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBalnc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100: 3063–3067
33. Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD, Streetly M, Dalgleish AG (2004) Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 22: 3269–3276
34. Speed DE, Galton DA, Swan A (1964) Melphalan in the treatment of myelomatosis. Br Med J 1: 1664–1669